Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Inc.

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, with a price target of $570.00. The co...

Alnylam Pharma (ALNY) Receives a Rating Update from a Top Analyst

In a report released on October 30, Luca Issi from RBC Capital maintained a Buy rating on Alnylam Pharma, with a price target of $500.00. The compa...

Alnylam Pharma (ALNY) Gets a Buy from RBC Capital

Alnylam Pharmaceuticals (($ALNY)) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals has announced a new clinical study t...

Alnylam Pharmaceuticals Launches Promising Phase 3 Study on Nucresiran for hATTR-PN

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Alnylam Pharma today and set a price target of $515.00. The company’s shares opened to...

Evercore ISI Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Barclays analyst Gena Wang maintained a Buy rating on Alnylam Pharma today and set a price target of $527.00. The company’s shares closed yesterday...

Alnylam Pharma (ALNY) Gets a Buy from Barclays

Alnylam Pharmaceuticals (($ALNY)) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals is conducting a pivotal Phase 3 clin...

Alnylam’s ZENITH Study: A New Horizon in Cardiovascular Treatment

In a report released today, William Pickering from Bernstein maintained a Buy rating on Alnylam Pharma, with a price target of $471.00. The company...

Market Cap	$59.82B	P/E Ratio	232.12
52W High	$495.55	52W Low	$205.87
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	32.9%	52W Position	79.6%
Overall Score	38	Value Score	40
Quality Score	--	Technical Score	36

EPS Current Est	$1.88	EPS Next Est	$7.22
EPS Growth Est	+284.0%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALNY	$436.38	-2.11%	1.30M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALNY	$436.38	-2.1%	1.30M
3
4
5
6

ALNY

ALNY

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Alnylam Pharmaceuticals Inc. Data in Excel

Get Alnylam Pharmaceuticals Inc. Data in Excel